Colorectal cancer 2-chlorodeoxyadenosine Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian Prognosis Mesenchymal stromal cells Survival Radiotherapy Cancer Stem Cells Radiofrequency ablation ALK rearrangement Adjuvant therapy Merkel cell carcinoma Lung adenocarcinoma BRAFV600-mutant melanoma Safety Antibody-drug conjugate EGFR Melanoma CARMN TNM classification Abdominal pain Ceritinib Anti-PD1 Adjuvant Anti-PD-1 antibody Cemiplimab Cutaneous squamous cell carcinoma Follow-up Locally advanced Metastatic Radiotherapy Surgical excision Treatment Biomarker Staging Brain Metastases Children Gastric bypass Cancer BRAFV600E Metastatic cSCC Allelic imbalance Circulating cell-free DNA ADN tumoral circulant COVID-19 Cell signalling Wnt Chemotherapy Immunohistochemistry ACTH Targeted therapy Crizotinib BRAFV600E mutation Resistance Immunomodulation Trametinib ALK Anti-PD1 blockade Bariatric surgery Osimertinib Advanced melanoma Androgen insensitivity Advanced Systemic therapy Sonic Hedgehog Cemiplimab BRAF V600E Polyomavirus AZD9291 Immune checkpoint inhibitor Dabrafenib Prevention Chemoresistance Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation Plasma Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy Anti-PD-1 Invasive cutaneous squamous cell carcinoma Anti-CTLA-4 Diagnosis Adjuvant FOLFOX BRAF V600-mutation Colorectal carcinoma Cancer bronchique non à petites cellules Biomarkers Histiocytosis Circulating tumor DNA Abscopal effect Anti-Tumor pharmacology Body mass index Antineoplastic agents Bone marrow niche Biliopancreatic diversion Adjuvant Adverse events Colon cancer Molecular targeted therapies Nivolumab BRAF Prognostic C797S Anti-PD-1 antibody AML Beta-catenin Acute generalized exanthematous pustulosis Non-small cell lung cancer Cancers of the Colon Immunotherapy Langerhans cell histiocytosis